Get informed when a big investor buys or sells
+ FollowOvervalued by 28.6% based on the discounted cash flow analysis.
Loading insider trades…
Loading congress trades…
| Market cap | $153.69 Million |
|---|---|
| Enterprise Value | $98.93 Million |
| Earnings per Share | $-1.65 |
| Beta | 0.68 |
| Outstanding Shares | 38,326,000 |
| P/E Ratio | -1.78 |
|---|---|
| PEG | 164.39 |
| Price to Sales | - |
| Price to Book Ratio | 4.01 |
| Enterprise Value to Revenue | - |
| Enterprise Value to EBIT | -1.77 |
| Enterprise Value to Net Income | -2 |
| Total Debt to Enterprise | 0.03 |
| Debt to Equity | 0.05 |
No data
No data available for the latest quarter.
No data available for the latest quarter.
Molecular Partners AG is a clinical-stage biopharmaceutical company that specializes in the discovery, development, and commercialization of novel therapeutic proteins, leveraging its proprietary DARPin® technology. Its pipeline features...